WuXi Biologics: The company's biomanufacturing business is expected to start production in the first quarter of 2026.

Wuxi Biologics stated on the investor interaction platform that the company's biomanufacturing business will complete the capacity construction of its first industrial project by 2025 and commence production in the first quarter of 2026. It has also connected with downstream customers and established cooperative relationships. Please continue to follow the company's information disclosure for further developments. The company's quadrivalent meningococcal conjugate vaccine is currently in Phase III clinical research stage, and the company will strictly follow relevant regulations and requirements of the national drug registration program to carry out related work.